• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Govt funds dry up to honour Indian scientists
  • Elsevier ranked Prof Ashok Pandey among top 5 scientists of India
  • A tribute to Father of Indian Green Revolution Dr M S Swaminathan
  • The Lancet was made for political activism- For 200 years, it has thrived on melodrama and scandal
  • Valo Therapeutics Announces Acquisition of Bruker Corporation’s Latest Mass Spectrometer Platform for Tumor Antigen Identification with ValoTx’s PeptiCHIP Technology
  • FABA and ABF Conduct Hands-on Training on CRISPR-Cas-Mediated Genome Editing in Plants
  • US FDA grants Orphan Drug Designation for CRO-67
  • Integrative Medicines (IM) Market to Grow with a High CAGR during 2023-2035; Increasing Adoption of Natural Remedies Around the World to Drive Market Growth
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    May 22, 2023

    Prof Rajeev Varshney becomes the 4th Indian Agricultural Scientist to be elected as Fellow of the Royal Society

    July 26, 2022

    We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO

    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Articles»YASHRAJ BIOTECHNOLOGY LIMITED (YBL) 20 YEARS OF EXCELLENCE IN TRANSFORMING WASTE TO WELL-BEING

YASHRAJ BIOTECHNOLOGY LIMITED (YBL) 20 YEARS OF EXCELLENCE IN TRANSFORMING WASTE TO WELL-BEING

0
By Biotech Express on February 6, 2019 Articles, Articles- Guestorials

Introduction

Progress is not about how we grow, it is about how we make a difference in lives of others! This is the guiding principle at Yashraj Biotechnology Limited (YBL), a pioneering biotechnology company located in Navi Mumbai, India. The founder members of the company Mr. Arvind Bhanushali, Mr. Bharat Dagha and Dr. Paresh Bhanushali started the company in 1999 and this year the company is celebrating its 20 years of
existence.

The company was established with a vision to be the best in the diagnostic field and make diagnostics
affordable and easily available to the common man. Today, YBL is a leading name in the in vitro diagnostic market, supplying high purity Antigens, Antibodies, proteins and enzymes to some of the world’s top 20
diagnostic companies.

From Bio-Medical Waste to Diagnostic Application Products: An Innovative Approach

YBL capitalizes on usefulness of the human biomedical waste generated by the hospitals for diagnostic
purposes by manufacturing Native Antigens (Table 1) which are purified from the effusions of patients
suffering from cancer, renal, and cardiac failures. In addition to diagnostic use, the manufacturing processes at YBL indirectly helps in reducing the environmental pollution due to disposal of human biomedical waste which is a major concern to the hospitals, the regulatory authorities and the citizens.

The Biomedical waste management teams at YBL have created a Pan India network to access Bio-medical fluids for extraction and purification of high quality Native and Recombinant Antigens in a time-effective manner.

State-of-the-Art Research & Development

YBL has a well-equipped Research & Development (R&D) unit in which a wide range of high-quality Antigens (Native and Recombinant), Proteins, Enzymes are manufactured using advanced chromatography systems like AKTA prime plus and AKTA Pure for protein purification.

The Recombinant R&D facility manufactures highly purified proteins and enzymes both with and without tags and by using different expression systems like Bacterial (E. coli), Mammalian (CHO, HeLa, HEK293, MCF7), Bacculovirus (Spodoptera frugiperda) Sf9/Sf21 insect cells and Yeast (Saccharomyces cerevisiae).

Highly specific and high affinity monoclonal and polyclonal Antibodies are developed and characterized by Surface Plasma Resonance (SPR) using Biacore T200 system. These Antibodies are validated by external agencies and certified for use in development of immunoassays like Enzyme-linked Immuno Sorbent Assay (ELISA), Flow Cytometry, Chemiluminescence Assays (CLIA) and Immunohistochemistry (IHC).

YBL products basket contains more than 25 Native and 22 Recombinant Antigens with a purity percentage ranging from 90-99% (To download YBL products booklet please write to marketing@yashrajbio.com).

Efficient Production and Rigorous Quality Checks
A seamless transition occurs between the R&D and the production unit for scaling up and mass production of protein. Standard operating procedures are followed to maintain batch to batch consistencies irrespective of capacity (from small to bulk production). The emphasis lies on the maintenance of long-term stability, specificity and purity of the products which is ensured by Quality Control. Rigorous testings are performed on multiple platforms like Roche Cobas e411 & c311 and Siemens Advia Centaur CP & XP analyzers.

Protein quantification and validation is done using ELISA, ECLIA, Immunonephelometry, Immunoturbidimetry and Latex Agglutination, SDS-PAGE, Western Blotting, HPLC, Crossed immunoelectrophoresis (CIE) and Mass-Spectrometry. Real and accelerated stability tests are performed for batch consistency and viral contamination is identified by performing PCR and USFDA approved CLIA techniques. Once the protein quality is confirmed and certified, they are properly labeled and packaged for a timely delivery to the customers worldwide.

Stem Cell & Antibody Phage Display: New Ventures
In the last 2 years, YBL is diversifying its R&D activities to develop IPSCs Stem Cell technology for drug discovery and screening. It has successfully developed methodologies to bio-bank peripheral blood mononuclear cells and erythroblast cell populations from cancer patients and healthy individuals (controls).

In 2018, YBL ventured into production of Recombinant Monoclonal Antibodies using Phage Display for Diagnostic & Research purpose. Currently, both the facilities are in initial stages of development and the products are expected to be available in the market by July 2020.

CSR at YBL: Grants and Awards Sponsorship
Every year YBL donates a percentage of the profit for Corporate Social Responsibility (CSR) initiatives like Healthcare and Education for the welfare of economically weaker section of the society. The amount depends on the profit generated and is decided by the Board. For more details please see http://yashraj.com/csr/

The YBL company’s major activities involve:

Isolation, purification and production of Native and Recombinant proteins;

Development of polyclonal and monoclonal Antibodies against
Immunogens;

Production of cell-derived Native Antigens using appropriate cell lines.

Moreover, YBL in collaboration with the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) sponsors the IFCC-Yashraj Biotechnology Limited Distinguished Clinical Chemist Award & IFCC-Yashraj Biotechnology Limited Distinguished Award for Contributions to Affordable In vitro Diagnostics to recognize researchers who have made significant contributions in this discipline.

Come and join us at Yashraj Biotechnology Limited in our quest to make diagnostics more affordable and accessible!

For any query please write to marketing@yashrajbio.com

Website: www.yashraj.com

Linkedin: linkedin.com/company/yashraj-biotechnology-ltd

Twitter handle: @YashrajBio

Facebook: Yashraj Biotechnology Ltd

Certifications:: ISO 9001: 2015 and ISO 13485: 2016

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Valo Therapeutics Announces Acquisition of Bruker Corporation’s Latest Mass Spectrometer Platform for Tumor Antigen Identification with ValoTx’s PeptiCHIP Technology

US FDA grants Orphan Drug Designation for CRO-67

Integrative Medicines (IM) Market to Grow with a High CAGR during 2023-2035; Increasing Adoption of Natural Remedies Around the World to Drive Market Growth

Leave A Reply Cancel Reply

Current Issue – October 2023
Upcoming Event

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Govt funds dry up to honour Indian scientists October 23, 2023
  • Elsevier ranked Prof Ashok Pandey among top 5 scientists of India October 22, 2023
  • A tribute to Father of Indian Green Revolution Dr M S Swaminathan October 21, 2023
  • The Lancet was made for political activism- For 200 years, it has thrived on melodrama and scandal October 15, 2023
  • Valo Therapeutics Announces Acquisition of Bruker Corporation’s Latest Mass Spectrometer Platform for Tumor Antigen Identification with ValoTx’s PeptiCHIP Technology October 12, 2023
  • FABA and ABF Conduct Hands-on Training on CRISPR-Cas-Mediated Genome Editing in Plants October 12, 2023
  • US FDA grants Orphan Drug Designation for CRO-67 October 10, 2023
  • Integrative Medicines (IM) Market to Grow with a High CAGR during 2023-2035; Increasing Adoption of Natural Remedies Around the World to Drive Market Growth October 5, 2023
  • Scientists create human embryo in lab without eggs, sperm September 23, 2023
  • Concord Biotech: Stock Market’s New Biotech entrant ready with IPO July 31, 2023
  • National Research Foundation (NRF): facing support and resistance from scientific communities! Why? July 25, 2023
  • Biodiversity- preserve or perish July 24, 2023
  • Dr Rajesh Gokhale assumes charge as Secretary of Department of Science and Technology July 23, 2023
  • Advancing allergy detection and management in India: A pathway to improved health July 23, 2023
  • Gujarat govt signs MOUs with 15 companies for ₹2000 cr in a single day July 22, 2023
  • Pune biotech firm announces cheaper drug for colorectal cancer July 21, 2023
  • Ambiq Propels Remote Healthcare Monitoring Sector Growth with New Ultra-Low Processors July 20, 2023
  • BMJ Open retracted a diabetes paper because it was funded by tobacco company July 19, 2023
  • Indian scientist made First Marwari horse foal through Embryo transfer technology July 12, 2023
  • Prof Rajeev Varshney becomes the 4th Indian Agricultural Scientist to be elected as Fellow of the Royal Society May 22, 2023
  • FABA holds Conference on Antimicrobial Resistance Stewardship Series May 22, 2023
  • COVID no longer a global health emergency, WHO says May 18, 2023
  • Chemist in India loses seven papers of biology, blames outsourcing of images May 17, 2023
  • Indian Research scholars express frustration over DST’s tweet, plan stir May 16, 2023
  • BioAsia 2023 to be held in February 24-26 in Telangana, India January 10, 2023
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt November 10, 2022
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian? November 1, 2022
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE October 31, 2022
  • Event: Australia’s biggest week in biotech kicks off in Perth October 26, 2022
  • $3 trillion growth reported for biotech sector in USA October 25, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.